QNRX · Quoin Pharmaceuticals Ltd. · Executive Compensation
$6.79
-0.11 (-1.59%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based upon the Company's current business plans and cash, cash equivalents, and investments on hand, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of the filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 14, 2026
Market Cap
$13.64M
Shares
2.01M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Dr. Michael Myers | Chief Executive Officer | $1,507,345 |
| Denise Carter | Chief Operating Officer Sally Lawlor Chief Financial Officer | $1,282,285 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dr. Michael Myers | Chief Executive Officer | $1,406,801 |
| Denise Carter | Chief Operating Officer | $1,211,262 |
| Gordon Dunn | Chief Financial Officer | $656,632 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dr. Michael Myers | Chief Executive Officer | $1,255,188 |
| Denise Carter | Chief Operating Officer | $1,070,966 |
| Gordon Dunn | Chief Financial Officer | $775,935 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dr. Michael Myers | Chief Executive Officer | $1,966,799 |
| Denise Carter | Chief Operating Officer | $1,805,402 |
| Gordon Dunn | Chief Financial Officer | $1,450,207 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Sember | director | Appointed | 2026-08-20 |
| Natalie Leong | director | Appointed | 2026-08-20 |
| James Culverwell | director | Appointed | 2026-08-20 |
| Dr. Dennis H. Langer | director | Appointed | 2026-08-20 |
| Joseph Cooper | director | Appointed | 2026-08-20 |
| Denise Carter | director | Appointed | 2026-08-20 |
| Dr. Michael Myers | director | Appointed | 2026-08-20 |
| Gordon Dunn | Chief Financial Officer | Terminated | 2025-08-27 |
| Sally Lawlor | Princial Accounting Officer | Appointed | 2025-08-21 |
| Sally Lawlor | Chief Financial Officer | Appointed | 2025-08-21 |
| Michael Sember | Director | Appointed | 2024-12-10 |
| Natalie Leong | Director | Appointed | 2024-12-10 |
| Dr. Dennis H. Langer | Director | Appointed | 2024-12-10 |
| Joseph Cooper | Director | Appointed | 2024-12-10 |
| Denise Carter | Director | Appointed | 2024-12-10 |
| James Culverwell | Director | Appointed | 2024-12-10 |
| Dr. Michael Myers | Director | Appointed | 2024-12-10 |